


Molecular Imaging: Dream or Reality

Helsinki, December 2011

Juhani Knuuti
Turku PET Centre
University of Turku and Turku University Hospital
Turku, Finland
Juhani.knuuti@utu.fi



**Turku PET
Centre**

Funding organisations



University of Turku, Turku, Finland



Åbo Akademi University, Turku, Finland



Hospital District of Southwest Finland



*Center of Excellence on Molecular Imaging in
Cardiovascular and Metabolic Research 2008 - 2013*



*IMAGE-HF (Finland-Canada)
TEKES-CIHR funded multicentre project about imaging
in heart failure*




In Vivo Molecular Imaging

- ❑ Definition of *in vivo* molecular imaging
- ❑ Molecular imaging methodology
- ❑ Translational aspects
- ❑ Examples of applications



Biomedical Imaging



Nanoscopic

In vitro tissue


In vivo non-clinical

Cell

Ex vivo



Clinical

Molecular Imaging in Medicine




Turku PET Centre


In vitro and Ex vivo tissue imaging



Immunohistologia



Autoradiografia




In vivo preclinical imaging

Mouse [^{18}F]FDG heart



Ax

Cor

Sag



Rat whole-body
PET and MRI





Mouse [^{18}F]FDG whole-body


PET

CT



PET/CT



Rat [^{18}F]CFT brain



Clinical Applications of PET and PET/CT



Imaging in 2020

- ❑ Individualized therapy requires individualized diagnostics
 - Non-invasive imaging
 - Molecular Imaging
 - Fusion imaging
- ❑ Prevention of disease requires early detection
 - Imaging for screening



PET imaging applications in drug discovery and development



Enhance pathway and target identification in living systems

Proof of mechanism
Species differences
PK/PD
ADME
Safety
Dose ranging
Drug delivery
Efficacy

Enhance the quality of lead compound selection in living systems

Phase 0 microdosing
Phase I-III trials
Efficacy
Safety
Human PK
Dose Selection
Bioavailability
Patient selection
Surrogate endpoints


Early identification of failure or success

Phase IV
Safety
Diagnosis & staging
Patient selection
Treatment planning

Molecular therapy and imaging package for clinical application



Challenges in Molecular Imaging




In Vivo Molecular Imaging


- ❑ Definition of *in vivo* molecular imaging
- ❑ Molecular imaging methodology
- ❑ Translational aspects
- ❑ Examples of applications




In Vivo Imaging Modalities




Positron Emission Tomography (**PET**)
Single Positron Emission Tomography (**SPECT**)




Computer Tomography (**CT**)



Magnetic Resonance Imaging (**MRI**)




Optical Imaging (**OI**)



UltraSound (**US**)

Comparison of Relative Strengths of Different Imaging Modalities



Complementary!



Comparison between different imaging modalities

Modality	Spatial resolution	Depth	Temporal resolution	Sensitivity	Molecular probe
PET	1–2 mm	No limit	10 s-min	pmol-fmol	ng
SPECT	0.5–1.5 mm	No limit	min	pmol	ng
Bioluminescence	3–5 mm	1–2 mm	sec-min	fmol	µg-mg
Fluorescence	2–3 mm	<1 mm	sec-min	pmol-fmol	µg-mg
MRI	25–100 µm	No limit	min-hrs	mmol	µg-mg
CT	50–200 µm	No limit	min	–	N/A
Ultrasound	50–500 µm	mm-cm	sec-min	–	µg-mg



Molecular imaging laboratory

- ❑ Autoradiography
- ❑ Micro CT
- ❑ Animal MRI
- ❑ Micro PET
- ❑ Optical imaging
- ❑ Multimodality systems (PET/CT/SPECT/MRI)
- ❑ Human scanners (SPECT, PET, MRI, CT, US)



Imaging – Requirements for international success

- Imaging infrastructure
- Expertise
- Critical mass of skills → Networking



Special expertise in small animal imaging in Finland

- ❑ Micro CT
- ❑ Animal MRI
- ❑ Micro PET(CT)
- ❑ Micro SPECT
- ❑ Optical imaging

Turku

Kuopio

Turku

Kuopio, Helsinki

Helsinki, Turku



Special expertise in human imaging research in Finland

☐ SPECT	Kuopio
☐ CT	Turku
☐ MRI	Turku, Helsinki, Kuopio
☐ PET	Turku
☐ Ultrasound	Turku, Helsinki, Tampere
☐ MEG	Helsinki
☐ Multimodality	Turku



Biomedical *in vivo* Imaging infrastructure in the Turku PET Centre Imaging Platform

Micro-CT



Optical imaging system



Animal US




3T MRI/PET



Philips 1,5 T
MRI



GE VCT PET/CT
64-slice CT



Fuji FLA-7000
Phosphor imaging
device



Siemens Inveon multimodality
Animal PET/CT



Animal/human
PET HRRT



GE D690 PET/CT



Human Digital
US



SIEMENS PET
HR+




Ex vivo

In vivo non-clinical

Clinical

Turku BioImaging



Nanoscopic


***In vitro* tissue**

***In vivo* non-clinical**

Cell




Ex vivo

Clinical



Master's Degree Programme in Biomedical Imaging

120 ECTS



A NEW INTERNATIONAL PROGRAMME IN BIOMEDICAL IMAGING LEADING TO A M.Sc. DEGREE (120 ECTS, 2 years)

- A Joint Degree Programme of the Department of Biosciences at Åbo Akademi University and the Medical Faculty at the University of Turku, Finland
- The programme covers a broad spectrum of diverse imaging technologies and provides the students with cutting-edge knowledge and good practical skills in a wide range of imaging methods
- The Master's programme is intended for students with a B.Sc. degree, equivalent to a Finnish B.Sc. degree, in the Life Sciences or applicable areas of biomedical sciences, engineering, physics, or chemistry

- Language of instruction: English

Tracers are the critical elements for molecular imaging

Partnering with
- Academic centers
- Industry

Tracers at Turku PET Centre

F-18 Tracers

[18F]FDG
 [18F]FDOPA
 [18F]CFT
 [18F]FTHA
 [18F]F⁻
 [18F]L165
 [18F]FETNIM
 [18F]FBPA
 [18F]FDA
 [18F]AH110691
 [18F]EF5
 [18F]DPA
 [18F]FEMPA
 [18F]Flutematomol

Ga-68 Tracers

Ga-DOTATOC
 Ga-Bombesin
 DOTAVAP-PEG-P2
 Ga-PAPP-A-NOTA
 Ga-[(3-EtOsal)₂Me₄BAPEN]⁺
 Ga-[(3-MeOsal)₂BAPDMEN]⁺
 Ga-[(3-MeOsal)₂Me₄BAPEN]⁺
 Ga[(sal)₂BAPDMEN]⁺
 Ga-ATSM
 Ga-DOTA
 Ga-DOTA-Bombesin
 Ga-NODAGA-Exendin
 Ga-NOTA
 Ga-NOTAVAP-Ab
 Ga-oligo (22mer)
 Ga-PAPP-A-NOTA

C-11 Tracers

[11C]Acetate
 [11C]Carfentanil
 [11C]CFT
 [11C]Choline
 [11C]CIT
 [11C]Deprenyl
 [11C]DOPA
 [11C]FLB457
 [11C]Flumazenil
 [11C]MeAIB
 [11C]Methionine
 [11C]MHED
 [11C]MP4A
 [11C]MTO
 [11C]NMSP
 [11C]NNC756
 [11C]Palmitic acid
 [11C]Raclopride
 [11C]SCH23390
 [11C]SCH39166
 [11C]WAY100635
 [11C]MP4B
 [11C]PIB
 [11C]AH110690
 [11C]PK 11195
 [11C]ORMA
 [11C]Madam
 [11C]Deuterium deprenyl
 [11C]TMSX
 [11C]PE21
 [11C]ORMB

O-15 Tracers

O-15-water
 O-15-CO
 O-15-O2

Cu-64 Tracers

Cu-64-Exendin

In Vivo Molecular Imaging

- ❑ Definition of *in vivo* molecular imaging
- ❑ Molecular imaging methodology
- ❑ Translational aspects
- ❑ Examples of applications




Models of human diseases

From phantoms....




Models of human diseases

...to small animals....



**LDL receptor- and
ApoB48 -deficient
mouse**




stenotic aortic valve region

Models of human



The model has been adopted from NCVC Osaka

...to larger animals....

- Pig models
 - CAD
 - Diabetes and hypercholesterolemia
 - Heart Failure
 - Post-MI 2 step LAD occlusion
 - Plaque
 - Catheter introduced targets




- Validation of models
 - Molecular imaging
 - Perfusion
 - Function
 - Histology



Models of human diseases


...to human carotid...

MRI-PET
(^{18}F -FDG)



Models of human diseases

...to human coronaries.



Myocardial FDG uptake suppressed by low carbohydrate, high fat diet
Dual gated PET/CT


Teräs et al. Eur J Nucl Med Mol Imaging 2009

Turku PET Centre, Finland




In Vivo Molecular Imaging

- ❑ Definition of *in vivo* molecular imaging
- ❑ Molecular imaging methodology
- ❑ Translational aspects
- ❑ Examples of applications

Analysis of Cardiac PET 15-O-water study




Hybrid PET/CT stress images



Perfusion in ml/g/min

LAD septal	2.0
ant.	2.4-2.6
LCX	2.9-3.2
RCA	2.0




Criteria:

Perfusion in ml/g/min

Normal > 2.5
Mildly abnormal 2.0-2.5
Clearly abnormal ≤ 2.0

Hybrid PET/CT vs. ICA + FFR

Vessel analysis in patients with intermediate likelihood of CAD, N=107



Kajander et al Circulation 2010

Perfusion quantitation

Saturation-recovery Turbo fast low

The model has been developed and transferred from Mie University

RI






Figure 2



Pärkkä et al, MRM 2006

Thank you



Turku PET Centre today

- A National Research Institute for imaging
 - University of Turku, Åbo Akademi University and Turku University Hospital
- 110 persons in staff and investigators
- Imaging devices
 - 6 PET/CT
 - GE Discovery VCT (whole-body PET/CT)
 - GE D690 (whole-body PET/CT)
 - Siemens HR+ (whole-body PET)
 - HRRT (brain/animal PET)
 - 2 Siemens Inveon (small animal PET/CT)
 - 1 PET/MRI 3.0T
 - 1 MRI: Philips 1.5T
 - 3 Ultrasound scanners
 - 2 Acuson (Doppler echocardiography)
 - VisualSonics Vevo (small animal ultrasound)
- Radiochemistry laboratory
 - 3 cyclotrons, 2 $^{68}\text{Ge}/^{68}\text{Ga}$ generators
 - 19 hot cells (13 in GMP)
- Facilities
 - 3000 m²
 - Clinical and preclinical imaging laboratories
- Research
 - Neurotransmission, cardiometabolic research, preclinical imaging and drug research, radiochemistry
 - >40 different tracers in routine use



www.pet.fi

Turku PET Centre Publications per year

